


---

<b>Product Name</b>	:	YL-5092
<b>Cat. No.</b>	:	PC-26021
<b>CAS No.</b>	:	3056857-07-6
<b>Molecular Formula</b>	:	C <sub>22</sub> H <sub>14</sub> F <sub>3</sub> N <sub>3</sub> O <sub>2</sub> S
<b>Molecular Weight</b>	:	441.43
<b>Target</b>	:	Histone Methyltransferase (HMTase)
<b>Solubility</b>	:	10 mM in DMSO



CAS: 3056857-07-6

## Biological Activity

YL-5092 is a highly potent and selective, first-in-class inhibitor of RNA m6A reader **YTHDC1** with IC<sub>50</sub> of 7.4 nM and SPR K<sub>d</sub> of 29.6 nM.

YL-5092 dose-dependently blocked the binding of substrate mimic, indicating a competitive inhibitor of substrate.

YL-5092 shows no activity against other RNA m6A readers, including YTHDC2, YTHDF1-3, IGF2BP1-3, and HNRNPA2B1.

YL-5092 treatment could dose-dependently stabilize YTHDC1 in MOLM-13 and U937 cells in cellular thermal shift assay (CETSA).

YL-5092 treatment substantially suppressed the proliferation and induced the differentiation and apoptosis of AML cells. also efficiently inhibited the colony-forming ability of CD34+ AML stem cells, but had no effect on normal hematopoietic stem cells and early progenitors (Lin- Sca1+ Kit+).

YL-5092 treatment impaired leukemogenesis and improved the animal survival rate in mouse AML xenograft models.

## References

Zhang H, et al. *Sci Transl Med*. 2026 Feb 4;18(835):eadu3137.

Shengyong Yang, et al. Discovery of a selective YTHDC1 inhibitor that targets acute myeloid leukemia.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: [tech@probechem.com](mailto:tech@probechem.com)

---